▷ Ready for Middle East Market Entry: Vazyme Presents its…

28.01.2022 – 06:00


Dubai, Vae (ots/PRNewswire)

Leading Chinese biotech company Vazyme (688105.SH) attended Medlab Middle East 2022 from January 24th to 27th at Dubai World Trade Center (DWTC). Recognized as the premier trade show for the medical laboratory industry, Medlab Middle East is a conference that brings together medical professionals from around the world to showcase the latest laboratory innovations and technologies. At booth no. Z5.H20, the company presented its complete product portfolio for COVID-19 testing solutions as well as advanced IVD products to the online and live event visitors. Most of the more than 500 visitors came from the Middle East, the rest came from India and Turkey, among others. The COVID-19 Antigen Rapid Test Kit, which provides a test result within 10 minutes and achieves an accuracy of 99.81%, was the most popular product.

“The fact that the omicron variant is spreading and hospitals and testing centers are under increasing pressure underscores the need to scale up production of rapid and reliable COVID-19 test kits to catch the new wave of infections. We want to support the medical community in the Middle East and Africa region in meeting this challenge. With our high-quality Covid-19 testing products and solutions that we will be showcasing at Medlab 2022, we can help support local efforts to fight the pandemic,” said Jenny Jiang, Vazyme’s International Business Manager.

The event showcased Vazyme’s full range of nucleic acid detection solutions, along with other products for COVID-19 detection, including a range of antigen detection kits, COVID-19 vaccine antibody evaluation solutions and raw materials for the detection solutions. One of the highlights of the exhibition, Vazyme’s automated nucleic acid extraction system has received market approval from the governments of the United Arab Emirates and Saudi Arabia, and the 2019-nCoV Triplex RT-qPCR Detection Kit has also recently been approved for the UAE market .

In its ten years of existence, Vazyme has consolidated its leadership position in China’s biotech industry with an extensive IVD production capacity of one million units per day. The Vazyme team in the MENA region consists of IVD product experts who offer local consumers full service and personal advice. Vazyme accelerated its global expansion in 2021 with the establishment of its first wholly owned overseas subsidiary in Indonesia. Together with the branches and warehouses in the USA, the EU and the Hong Kong SAR, customers worldwide can be served and looked after.

“This year we are celebrating the 10th anniversary of our company since its inception. As pioneers and innovators in life sciences, at Vazyme we are committed to using science and technology to improve people’s health and quality of life by addressing unmet medical needs around the world, while adhering to the highest standards of ethics, accountability and… maintain professionalism. Our R&D focused approach allows us to continually innovate and serve our customers with new products and solutions. We will continue to work with our partners around the world in the future and build on our past efforts to improve medical capabilities in the fight against serious diseases,” said Jenny Jiang.

Photo – https://mma.prnewswire.com/media/1735282/image_5016869_9915665.jpg

Press contact:

Weiru Hong +86 25-83772625 [email protected]

Original content by: Vazyme, transmitted by news aktuell


Leave a Reply

Your email address will not be published.